MNCs Bank On China Generics Market
This article was originally published in PharmAsia News
Executive Summary
Many multinational companies have been planning to tap the huge potential generic drug market in China. Recently, Novartis subsidiary Sandoz China acquired Grunenthal's factory for $35 million to boost Sandoz's generics production for the China and Asia markets. Bayer has also been stepping up efforts to expand its over-the-counter drug strategy in China. Generics represent an important business for MNCs, which enjoy a good market base and prices much higher than similar domestic products. However, analysts note that the trend may be influenced by many factors, such as the government's policies on pricing and health insurance, consumers' preference for mid- to low-end generic drugs and pharma companies' managerial ability to address rapid changes in the local market conditions. (Click here for more)
You may also be interested in...
Alvotech Highlights Lack Of Simponi Rivals As It Delivers Golimumab Results
Alvotech has just become the first company to announce positive topline results from a confirmatory clinical study for a proposed golimumab rival to Simponi and Simponi Aria – and moreover, the firm sees limited competition from other biosimilars on the horizon.
Xbrane Assembles The Troops As FDA Says No To Lucentis Biosimilar
Xbrane Biopharma was riding the crest of a wave with the EU launch of its biosimilar to Lucentis, following years of toil and investment. However, plans to roll out the product in the US will have to be pushed back – likely – into the middle of 2025, following a US FDA complete response letter.
UK MHRA Updates Assistive Tech And Borderline Regulations
Device classification themes were uppermost in April for the UK regulator, which issued key guidance in two areas prone to complexities. It also contributed to the MedTech Directorate’s one-year progress report.